Document 2822
 DOCN  M94A2822
 TI    CD4 cell count of HIV1 asymptomatic patients remains stable under
       cyclosporin A.
 DT    9412
 AU    Levy R; Tourani JM; Jais JP; Even P; Andrieu JM; Hopital Laennec
       Universite Paris V, France.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):217 (abstract no. PB0298). Unique
       Identifier : AIDSLINE ICA10/94369753
 AB    OBJECTIVE: We conducted a pilot study to test whether CSA could
       slow-down the CD4 cell count decline in asymptomatic HIV-1 infected
       patients (pts) by decreasing virus replication associated with CD4 cell
       activation and/or suppressing virus induced immune/auto-immune
       phenomena). METHODS: From Sept 1985 to Nov 1987 all HIV-1 seropositive
       pts followed at our institution having signed informed consent with CDC
       stage II/III and CD4 cells between 300-600/microliters were given CSA
       twice daily at 3.75 mg/kg. Dose was adapted to reach plasma levels of
       100 to 300 ng/ml. Biological and physical examinations were regularly
       done. RESULTS: 27 pts were enrolled in the study. No pt was withdrawn
       from analysis. There were 22 male, 5 females. (homosex: 19, heterosex:
       4, IVDA: 4), mean age: 37 years (min: 23--max: 68). There were 11 pts
       CDC II, 16 CDCIII. Initial median CD4 cell count (cells/microliters) was
       :523 (min 302--max 587). Median duration of CSA treatment was 11 months
       (min: 2, max 64). Median follow-up (FU) after CSA cessation was 45
       months (min: 2, max: 85), Toxicities were: paresthesia grade II: 5, III:
       1, renal grade II: 1, III: 1, IV: 12, anemia or thrombopenia grade II:
       1, III: 2, IV: 1, hepatic grade II: 2, Grade III: 2. Reasons for CSA
       cessation were: CD4 decrease: 7; renal toxicity: 7, pts wish: 5,
       thrombopenia: 3, hepatitis 2, paresthesia: 1, hemolytic anemia: 1,
       hypertension: 1. Under CSA no pt evolved towards AIDS. Results of
       repeated analysis measures of variances* (BMDP5V program) was done:
       TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSION: During CSA treatment
       (median duration 11 months) the CD4 cell count remained stable and no
       clinical AIDS occurred. During the FU period following CSA cessation
       (median 45 months) the CD4 cell count decreased at its usual rate.
 DE    Autoimmunity/DRUG EFFECTS  Bone Marrow Diseases/CHEMICALLY INDUCED
       Cyclosporine/ADVERSE EFFECTS/*PHARMACOLOGY/THERAPEUTIC USE  Drug
       Evaluation  Human  HIV Core Protein p24/BLOOD  HIV
       Infections/BLOOD/*DRUG THERAPY/IMMUNOLOGY  HIV-1/DRUG EFFECTS/PHYSIOLOGY
       Kidney Diseases/CHEMICALLY INDUCED  Leukocyte Count/*DRUG EFFECTS
       Paresthesia/CHEMICALLY INDUCED  Pilot Projects  Treatment Outcome  *T4
       Lymphocytes  Virus Replication/DRUG EFFECTS  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).